Supernus Pharmaceuticals
Manufacturing · Maryland, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
9715 Key West Ave, Rockville, Maryland, ...Phone Number
(301) 838-2500Website
www.supernus.comRevenue
$830.4 MillionStock Symbol
SUPNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system (CNS) diseases. Its portfolio includes treatments for epilepsy, ADHD, Parkinson’s disease, migraine, and other neurological disorders. The company combines internal research with strategic acquisitions to deliver medicines that address unmet patient needs while advancing a pipeline of novel CNS therapies.Explore more
Supernus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Supernus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Supernus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Supernus Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Supernus Pharmaceuticals
Website visits: Recent activity has been detected on your website
Supernus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Supernus Pharmaceuticals has new funding data
Check out if Supernus Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Supernus Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Supernus Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Supernus Pharmaceuticals
Compare insights from companies similar to Supernus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Supernus Pharmaceuticals
$830.4M
501-1,000
Public
$80M
2005
TD
Timothy DecSenior Vice President Chief Financial Officer
Company Profile Activity
Activity Insights
Supernus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Supernus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Supernus Pharmaceuticals.
Supernus Pharmaceuticals financials insights
Gather financial insights about Supernus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Debt
$30M
2012
Stock Offering
$50M
Supernus Pharmaceuticals Tech Stack
A closer look at the technologies used by Supernus Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Person-Based
Layoffs, Mergers
Person-Based
Mergers & Acquisitions
Open Position
Open Position
Supernus Pharmaceuticals News & Media
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuseWhy Supernus Pharmaceuticals Stock Topped the Market Today
It's effecting a "merger of equals" with a peer.Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, Aug. 3, 2026 /PRNewswire/ -- Ademi LLP is investigating Supernus (Nasdaq: SUPN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Indivior Pharmaceuticals. Click here to learn how to join our investigation and obtain...Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Supernus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system (CNS) diseases. Its portfolio includes treatments for epilepsy, ADHD, Parkinson’s disease, migraine, and other neurological disorders. The company combines internal research with strategic acquisitions to... Read More
